On April 6, 2026 DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage whole-genome cell-free DNA (cfDNA) assays for cancer detection and monitoring, reported it will present five poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2026 Annual Meeting, taking place April 17–22, 2026 in San Diego, CA. The presentations highlight advances across DELFI’s platform, including lung cancer subtyping, immunotherapy response prediction, the clinical utility of ctDNA-based molecular response, treatment monitoring on ultra high-throughput, next-generation sequencing platforms, and colorectal cancer treatment response monitoring.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This year’s AACR (Free AACR Whitepaper) presentations reflect the breadth and maturity of our AI-driven, computational platform," said Susan Tousi, CEO. "From early detection to treatment monitoring, we’re generating clinical evidence across the cancer continuum that reinforces the power of genome-wide cfDNA analysis combined with AI. These five abstracts represent meaningful contributions from our team and our academic collaborators at Johns Hopkins and the Netherlands Cancer Institute."
Poster Presentations at AACR (Free AACR Whitepaper) 2026
Sunday, April 19 | 2:00–5:00 PM PT
Cell-Free DNA Fragmentome Profiles Predict Immunotherapy Response
Session: Liquid Biopsies: Circulating Nucleic Acids 1
Poster Section 44, Board 15 | Abstract #1134
Presenter: Valsamo Anagnostou, MD, PhD, Johns Hopkins University
Lung Cancer Subtyping Using Cell-Free DNA Fragmentomes and Protein Biomarkers
Session: Liquid Biopsies: Circulating Nucleic Acids 1
Poster Section 44, Board 16 | Abstract #1135
Presenter: Laurel Millberg, MSc, DELFI Diagnostics
Clinical Utility of Landmark ctDNA Molecular Response as an Early Indicator of Immunotherapy Outcomes in Lung Cancer
Session: Liquid Biopsy: Multi-Analyte and Multi-Omic
Poster Section 5, Board 17 | Abstract #110
Presenter: Jaime Wehr, MS, Johns Hopkins University
Monday, April 20 | 2:00–5:00 PM PT
Enhanced cfDNA Fragmentation-Based Treatment Monitoring on the Ultima Genomics Platform
Session: Liquid Biopsies: Circulating Nucleic Acids 3
Poster Section 45, Board 24 | Abstract #3863
Presenter: Laurel Millberg, MSc, DELFI Diagnostics
Tuesday, April 21 | 9:00 AM–12:00 PM PT
Cell-Free DNA Fragmentomes for Treatment Response Monitoring in Patients with Metastatic Colorectal Cancer: The DOLPHIN Study
Session: Liquid Biopsies: Circulating Nucleic Acids 4
Poster Section 45, Board 20 | Abstract #5325
Presenter: Denise van Steijn, MSc, Netherlands Cancer Institute
The five presentations reflect the expanding clinical evidence base for DELFI’s technology platform, which uses AI and machine learning to analyze genome-wide patterns of cell-free DNA fragmentation in blood. The research spans early detection, cancer subtyping, immunotherapy response prediction, and treatment monitoring across multiple cancer types and sequencing platforms.
In early detection, DELFI has clinically validated FirstLook Lung, a blood-based test designed to improve early detection of lung cancer, the leading cause of cancer death in the United States. New data being presented at AACR (Free AACR Whitepaper) 2026 extend the platform’s capabilities into lung cancer subtyping and immunotherapy response prediction, demonstrating how fragmentation patterns and protein biomarkers can provide clinical insights beyond initial detection.
On the treatment-monitoring front, DELFI-TF*, the company’s tumor-fraction-based monitoring solution, continues to generate clinical validation data across cancer types. The DOLPHIN study presentation describes a multicenter, prospective, observational study from the Netherlands Cancer Institute that examines new potential applications for cfDNA-based treatment response monitoring in ~500 colorectal cancer patients treated with systemic chemotherapy.
Additionally, new DELFI-TF data generated on the Ultima Genomics platform underscore the adaptability of DELFI’s core genomics technology and identify promising avenues for performance enhancement in future product generations.
"We are excited to present our latest work in early detection, treatment monitoring, subtyping, and technology innovation, " said Amoolya Singh, PhD, Chief Technology Officer. "We continue to believe that the sensitivity, low cost, and versatility of our technical approach position us well for continued scientific discovery and product development."
(Press release, Delfi Diagnostics, APR 6, 2026, View Source [SID1234664188])